Wegovy vs. Rybelsus
Wegovy and Rybelsus are both semaglutide-based drugs, but their administration methods and approvals differ significantly. Wegovy is an injectable GLP-1 receptor agonist for chronic weight management, while Rybelsus is an oral formulation for type 2 diabetes. Wegovy delivers more pronounced weight loss (15% bodyweight) compared to Rybelsus’s HbA1c reductions and moderate weight effects. Wegovy has no off-label uses, whereas Rybelsus is occasionally used off-label for weight management. Common side effects of both drugs include nausea, but Rybelsus may pose higher risks of gastrointestinal discomfort. Wegovy is far more expensive, averaging $1,375/month, compared to Rybelsus’s $875/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions